German chemical and pharmaceutical company Bayer AG (BAYN.XE) said Tuesday it has received European Commission approval for its Xarelto drug to prevent deep vein thrombosis and treat pulmonary embolism.
-Xarelto, also known as Rivaroxaban, is the only oral blood thinner approved for this indication within the European Union.
-Pulmonary embolism occurs when a blood clot in the deep veins of the leg or pelvis detaches and travels to the lung via the heart, where it can block one of the pulmonary arteries.
-Earlier this month, Bayer reiterated its estimate of peak sales potential above EUR2 billion for Xarelto.
-The Xarelto treatment resulted in significantly lower rates of major bleeding among patients in a phase III study.
-"As a new treatment option, rivaroxaban offers a single-drug solution that works as fast as injectable enoxaparin and can provide protection for as long as needed," Professor Harry Bueller of the Academic Medical Center in Amsterdam, who led the clinical trial program, said.
-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500
Subscribe to WSJ: http://online.wsj.com?mod=djnwires